Identification of a NACC1-Regulated Gene Signature Implicated in the Features of Triple-Negative Breast Cancer
暂无分享,去创建一个
Jin-Ming Yang | Jianxun Song | Xiaofang Xiong | X. Ren | C. Ngule | A. O. Akinyemi | Xia Liu | Felix Oyelami | Hami Hemati | Oluwafunminiyi Obaleye | Jin-Ming Yang | Jianxun Song | Xia Liu
[1] P. Ordóñez-Morán,et al. Challenges for Triple Negative Breast Cancer Treatment: Defeating Heterogeneity and Cancer Stemness , 2022, Cancers.
[2] Jingqing Yang,et al. Expression of NAC1 Restrains the Memory Formation of CD8+ T Cells during Viral Infection , 2022, Viruses.
[3] Liang Yang,et al. Hypoxia, a key factor in the immune microenvironment. , 2022, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[4] Jingqing Yang,et al. Tumorous expression of NAC1 restrains antitumor immunity through the LDHA-mediated immune evasion , 2022, Journal for ImmunoTherapy of Cancer.
[5] M. Di Nicola,et al. BCL6 and the Notch pathway: a signaling axis leading to a novel druggable biotarget in triple negative breast cancer , 2022, Cellular Oncology.
[6] Jianlong Wang,et al. NAC1 modulates autoimmunity by suppressing regulatory T cell–mediated tolerance , 2022, bioRxiv.
[7] Zhaohui S. Qin,et al. UALCAN: An update to the integrated cancer data analysis platform , 2022, Neoplasia.
[8] Shannon E. McCarthy,et al. Quiescent cancer cells resist T cell attack by forming an immunosuppressive niche , 2021, Cell.
[9] H. Tang,et al. Identification of Five Cytotoxicity-Related Genes Involved in the Progression of Triple-Negative Breast Cancer , 2022, Frontiers in Genetics.
[10] Sharon Koorse Germans,et al. The Role of Breast Cancer Stem Cells in Chemoresistance and Metastasis in Triple-Negative Breast Cancer , 2021, Cancers.
[11] L. Gianni,et al. Treatment landscape of triple-negative breast cancer — expanded options, evolving needs , 2021, Nature Reviews Clinical Oncology.
[12] Nadezhda T. Doncheva,et al. Correction to ‘The STRING database in 2021: customizable protein–protein networks, and functional characterization of user-uploaded gene/measurement sets’ , 2021, Nucleic acids research.
[13] A. Lánczky,et al. Web-Based Survival Analysis Tool Tailored for Medical Research (KMplot): Development and Implementation , 2021, Journal of medical Internet research.
[14] J. Lathia,et al. Cancer stem cell–immune cell crosstalk in tumour progression , 2021, Nature Reviews Cancer.
[15] J. Gao,et al. CDK1 promotes the stemness of lung cancer cells through interacting with Sox2 , 2021, Clinical and Translational Oncology.
[16] T. Ho,et al. ZMYND8 preferentially binds phosphorylated EZH2 to promote a PRC2-dependent to -independent function switch in hypoxia-inducible factor–activated cancer , 2021, Proceedings of the National Academy of Sciences.
[17] B. Peethambaran,et al. Regulation of cancer stem cells in triple negative breast cancer , 2021, Cancer drug resistance.
[18] R. DePinho,et al. Cancer Stemness Meets Immunity: From Mechanism to Therapy , 2021, Cell reports.
[19] Bin Xu,et al. Identification of biomarkers, pathways and potential therapeutic target for docetaxel resistant prostate cancer , 2021, Bioengineered.
[20] Xijin Ge. iDEP Web Application for RNA-Seq Data Analysis. , 2021, Methods in molecular biology.
[21] S. Chouaib,et al. Tumor Hypoxia Regulates Immune Escape/Invasion: Influence on Angiogenesis and Potential Impact of Hypoxic Biomarkers on Cancer Therapies , 2021, Frontiers in Immunology.
[22] B. Győrffy,et al. TNMplot.com: A Web Tool for the Comparison of Gene Expression in Normal, Tumor and Metastatic Tissues , 2020, bioRxiv.
[23] Navid Nezafat,et al. Identification of Potential Biomarkers in Hepatocellular Carcinoma: A Network-Based Approach , 2020, Informatics in Medicine Unlocked.
[24] X. Wan,et al. Hypoxia induces an endometrial cancer stem-like cell phenotype via HIF-dependent demethylation of SOX2 mRNA , 2020, Oncogenesis.
[25] Ping Huang,et al. Integrative stemness characteristics associated with prognosis and the immune microenvironment in esophageal cancer. , 2020, Pharmacological research.
[26] K. Hu,et al. Transcription factor NFYA promotes G1/S cell cycle transition and cell proliferation by transactivating cyclin D1 and CDK4 in clear cell renal cell carcinoma. , 2020, American journal of cancer research.
[27] Haosheng Jin,et al. CDK1, CCNB1, and CCNB2 are Prognostic Biomarkers and Correlated with Immune Infiltration in Hepatocellular Carcinoma , 2020, Medical science monitor : international medical journal of experimental and clinical research.
[28] Xiaole Shirley Liu,et al. TIMER2.0 for analysis of tumor-infiltrating immune cells , 2020, Nucleic Acids Res..
[29] V. Gopalan,et al. Plasticity of Cancer Stem Cell: Origin and Role in Disease Progression and Therapy Resistance , 2020, Stem Cell Reviews and Reports.
[30] R. Mantovani,et al. Overexpression and alternative splicing of NF-YA in breast cancer , 2019, Scientific Reports.
[31] Joseph O Deasy,et al. Robust and interpretable PAM50 reclassification exhibits survival advantage for myoepithelial and immune phenotypes , 2019, npj Breast Cancer.
[32] Jan Baumbach,et al. Comprehensive evaluation of transcriptome-based cell-type quantification methods for immuno-oncology , 2019, Bioinform..
[33] Alireza Hadj Khodabakhshi,et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets , 2019, Nature Communications.
[34] Jiong Deng,et al. Iron-dependent CDK1 activity promotes lung carcinogenesis via activation of the GP130/STAT3 signaling pathway , 2019, Cell Death & Disease.
[35] Lydia Y. Liu,et al. Molecular landmarks of tumor hypoxia across cancer types , 2019, Nature Genetics.
[36] J. Deasy,et al. Robust and interpretable PAM50 reclassification exhibits survival advantage for myoepithelial and immune phenotypes , 2018, npj Breast Cancer.
[37] Allen W. Zhang,et al. Cancer stemness, intratumoral heterogeneity, and immune response across cancers , 2018, Proceedings of the National Academy of Sciences.
[38] Eun Woo Son,et al. iDEP: an integrated web application for differential expression and pathway analysis of RNA-Seq data , 2018, BMC Bioinformatics.
[39] X. Liu,et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response , 2018, Nature Medicine.
[40] Zheng Zhang,et al. Gene regulatory network construction identified NFYA as a diffuse subtype-specific prognostic factor in gastric cancer , 2018, International journal of oncology.
[41] Liang-Chih Liu,et al. EZH2 promotes migration and invasion of triple-negative breast cancer cells via regulating TIMP2-MMP-2/-9 pathway. , 2018, American journal of cancer research.
[42] Jin-Ming Yang,et al. Silencing of NAC1 Expression Induces Cancer Cells Oxidative Stress in Hypoxia and Potentiates the Therapeutic Activity of Elesclomol , 2017, Front. Pharmacol..
[43] C. Lindskog,et al. A pathology atlas of the human cancer transcriptome , 2017, Science.
[44] Chad J. Creighton,et al. UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses , 2017, Neoplasia.
[45] Yuhchyau Chen,et al. Cisplatin treatment increases stemness through upregulation of hypoxia‐inducible factors by interleukin‐6 in non‐small cell lung cancer , 2016, Cancer science.
[46] S. Masood. Breast Cancer Subtypes: Morphologic and Biologic Characterization , 2016, Women's health.
[47] Ching-Seng Ang,et al. FunRich: An open access standalone functional enrichment and interaction network analysis tool , 2015, Proteomics.
[48] H. Lyng,et al. The tumour hypoxia marker pimonidazole reflects a transcriptional programme associated with aggressive prostate cancer , 2014, British Journal of Cancer.
[49] G. Getz,et al. Inferring tumour purity and stromal and immune cell admixture from expression data , 2013, Nature Communications.
[50] Benjamin E. Gross,et al. Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.
[51] A. Harris,et al. Large meta-analysis of multiple cancers reveals a common, compact and highly prognostic hypoxia metagene , 2010, British Journal of Cancer.
[52] Crispin J. Miller,et al. Large meta-analysis of multiple cancers reveals a common, compact and highly prognostic hypoxia metagene , 2010, British Journal of Cancer.
[53] J. Russo,et al. ERalpha-negative and triple negative breast cancer: molecular features and potential therapeutic approaches. , 2009, Biochimica et biophysica acta.
[54] Sean R. Davis,et al. GEOquery: a bridge between the Gene Expression Omnibus (GEO) and BioConductor , 2007, Bioinform..
[55] Crispin J. Miller,et al. Relation of a hypoxia metagene derived from head and neck cancer to prognosis of multiple cancers. , 2007, Cancer research.
[56] I. Shih,et al. A BTB/POZ protein, NAC-1, is related to tumor recurrence and is essential for tumor growth and survival , 2006, Proceedings of the National Academy of Sciences.
[57] P. Defossez,et al. Born to bind: the BTB protein–protein interaction domain , 2006, BioEssays : news and reviews in molecular, cellular and developmental biology.
[58] Seon-Young Kim,et al. PAGE: Parametric Analysis of Gene Set Enrichment , 2005, BMC Bioinform..